GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Cyclically Adjusted Price-to-FCF

Peptron (XKRX:087010) Cyclically Adjusted Price-to-FCF : (As of Jun. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Peptron Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Peptron's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Cyclically Adjusted Price-to-FCF Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Peptron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Peptron's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Peptron's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Peptron's Cyclically Adjusted Price-to-FCF falls into.



Peptron Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Peptron's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Peptron's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-174.389/118.8477*118.8477
=-174.389

Current CPI (Mar. 2024) = 118.8477.

Peptron Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 99.353 0.000
201409 -145.632 99.608 -173.761
201412 -3.099 99.098 -3.717
201503 -95.546 99.720 -113.873
201506 -16.852 100.050 -20.018
201509 -82.004 100.110 -97.353
201512 -57.572 100.220 -68.273
201603 -59.956 100.560 -70.860
201606 -103.461 100.790 -121.997
201609 -83.000 101.460 -97.224
201612 -241.768 101.560 -282.922
201703 -417.547 102.850 -482.494
201706 -206.871 102.610 -239.608
201709 -358.450 103.490 -411.643
201712 -722.440 102.990 -833.676
201803 -97.617 104.100 -111.446
201806 -155.551 104.130 -177.537
201809 -203.272 105.650 -228.665
201812 -232.247 104.350 -264.514
201903 -122.122 104.490 -138.902
201906 -385.782 104.880 -437.160
201909 -207.139 105.200 -234.011
201912 -255.202 105.120 -288.529
202003 -221.541 105.540 -249.475
202006 -251.360 104.870 -284.863
202009 -209.830 106.200 -234.819
202012 -429.953 105.765 -483.135
202103 -237.269 107.357 -262.664
202106 -27.625 107.579 -30.519
202109 -198.260 108.759 -216.651
202112 -88.393 109.676 -95.785
202203 -206.923 111.806 -219.956
202206 -133.528 114.083 -139.105
202209 -151.626 114.831 -156.929
202212 -158.653 115.200 -163.676
202303 -149.637 116.550 -152.588
202306 -177.776 117.140 -180.368
202309 -162.382 119.111 -162.023
202312 -140.244 118.848 -140.244
202403 -174.389 118.848 -174.389

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Peptron  (XKRX:087010) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Peptron Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Peptron's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron (XKRX:087010) Business Description

Industry
Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines